肝细胞癌患者经动脉栓塞治疗的美国成本效果分析数据集

数据集获取（Figshare）

• 源站标题：Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
• DOI：10.6084/m9.figshare.24038301.v1
• 发布日期：2023-08-26
• 文件数：3 个
• 文件总体积：239.74 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Transarterial_therapies_in_patients_with_hepatocellular_carcinoma_eligible_for_transarterial_embolization_a_US_cost-effectiveness_analysis/24038301

命令行下载

curl -L -o "ijme_a_2248840_sm0270.docx" "https://ndownloader.figshare.com/files/42149910"
curl -L -o "ijme_a_2248840_sm0239.pdf" "https://ndownloader.figshare.com/files/42149913"
curl -L -o "ijme_a_2248840_sm0238.docx" "https://ndownloader.figshare.com/files/42149916"

文件清单

• ijme_a_2248840_sm0270.docx（28.54 KB）
• ijme_a_2248840_sm0239.pdf（96.09 KB）
• ijme_a_2248840_sm0238.docx（115.10 KB）

文件总体积 239.74 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).
A cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a “watch and wait” state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature.
At five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained.
TARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators.
The Barcelona Clinic Liver Cancer guideline recommends the use of transarterial radioembolization (TARE), conventional (cTACE), or drug-eluting bead transarterial chemoembolization (DEE-TACE) for treating hepatocellular carcinoma (HCC). This study evaluated the cost-effectiveness of TARE versus two alternative embolization treatments (cTACE and DEE-TACE) in treating patients with unresectable early- to intermediate-stage HCC.
A cohort-based Markov model was developed to a

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.24038301.v1（source: https://tandf.figshare.com/articles/dataset/Transarterial_therapies_in_patients_with_hepatocellular_carcinoma_eligible_for_transarterial_embolization_a_US_cost-effectiveness_analysis/24038301）。